Answers are grounded in this paper and cite their sources.
There are sufficient diagnostic and prospective validation studies to fulfill the US Food and Drug Administration criteria for a biomarker to support the inclusion of corneal confocal microscopy as a primary end point in clinical trials of disease-modifying therapies in diabetic neuropathy.
No takes yet. Share an insight, caveat, or question.
Petropoulos et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: